Key issues in the clinical development and implementation of TB vaccines in South Africa

Tuberculosis

Volumn 92, Issue 5, 2012, Pages 359-364

  Rustomjee, R ^a   McLeod, R ^a   Hanekom, W ^b   Steel, G ^c   Mahomed, H ^b   Hawkridge, A ^d   Welte, A ^e   Sinanovic, E ^f   Loots, G ^g   Grobler, A ^h   Mvusi, L ⁱ   Gray, G ^j   Hesseling, A ^e   Ginsberg, A ^k   Lienhardt, C ^l   Shea, J ^m   Tong, X ^a   Lockhart, S ^a   Churchyard, G J ⁿ  

^a Emergent Product Development   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Management Sciences for Health   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g Department of Health ^*  (South Africa)

^h UNIVERSITY OF KWAZULU NATAL   (South Africa)

ⁱ Department of Health   (South Africa)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k Scientific Affairs AERAS   (United States)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m Oxford Emergent Tuberculosis Consortium   (United Kingdom)

ⁿ AURUM INSTITUTE   (South Africa)

more..

Author keywords

Epidemiology; MVA85A; Trials; Tuberculosis; Vaccines

Indexed keywords

BCG VACCINE;

AGE DISTRIBUTION; BCG VACCINATION; CLINICAL DEVELOPMENT PLAN; DRUG SCREENING; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; SOUTH AFRICA; TUBERCULOSIS;

EID: 84865468784     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2012.05.001     Document Type: Note

References (28)

1. S.E. Kaufmann Fact and fiction in tuberculosis vaccine research 10 years later Lancet ID 11 2011 633
2. S.E. Kaufmann Fact and fiction in tuberculosis vaccine research: 10 years later Lancet ID 11 2011 633 (Pubitemid 43261442)
3. Stop TB Partnership and WHO Global plan to stop TB, 2011-2015: transforming the fight towards elimination of tuberculosis 2010 WHO Geneva
4. H. McShane Tuberculosis vaccines: beyond bacille Calmette-Guérin Phil Trans R Soc B 366 2011 2782
5. B.B. Trunz, P. Fine, and C. Dye Effect of BCG vaccination on childhood tuberculosis tuberculosis meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness Lancet 367 9517 2006 Apr 8 1173 1180
6. http://www.stoptb.org/wg/new-vaccines/assets/documents/ TB%20Vaccine%20Pipeline%2010%20-%2003%2021%2011.pdf
7. A. Stoten Human vaccines profile; Oxford Emergent Tuberculosis Consortium Hum Vaccin 7 8 2011 1 2
8. R. Wood, S.D. Lawn, J. Caldwell, R. Kaplan, K. Middelkoop, and L.G. Bekker Burden of new and recurrent tuberculosis in a major South African city stratified by age and HIV-status PLoS One 6 10 2011 e25098 Epub 2011 Oct 10
9. World Health Organization Sixteenth global report on tuberculosis 2011 www.who.int/tb/publications/global-report/
10. A. Hawkridge Clinical studies of TB vaccines Hum Vaccin 5 11 2009 Nov 773 776
11. Abdool Karim S. South African research in HIV/AIDs and TB. http://www.nhrc.org.za/wp-content/uploads/2011/09/presentations/akarim.pdf.
12. A. Hawkridge, M. Hatherill, F. Little on behalf of the South African BCG trial team A randomized trial comparing the efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis disease in infants and young children BMJ 337 a2052 2008 Nov 13 10.1136/bmj.a2052
13. S. Moyo, S. Verver, and A. Hawkridge Tuberculosis case finding for vaccine trials in young children in high-incidence setting: a randomized control trial Int J Tuberc Lung Dis 16 2 2012 185 191
14. H. Mahomed, A. Hawkridge, and S. Verver The tuberculin skin test versus QuantiFERON TB Gold® in predicting tuberculosis disease in an adolescent cohort study in South Africa PLoS One 6 3 2011 Mar 29 e1
15. K.S. Mate, B. Bennett, and W. Mphatswe Challenges for routine health system data management in a large public programme to prevent mother-to-child HIV transmission in South Africa PLoS One 4 5 2009 e5483
16. http://www.aeras.org
17. http://www.tbvaccine2010.org/uploads/Mgone-Charles-Thursday-September- 23rd-Presentation.pdf
18. http://europa.eu/rapid/pressReleasesAction.do?reference=MEMO/11/ 396&format=HTML&aged=0&language=EN&guiLanguage=en
19. http://www.action.org/site/print/
20. A.M. Checkley, and H. McShane Tuberculosis vaccines: progress and challenges Trends Pharmacol Sci 32 10 2011 Oct 601 606
21. B.M. Kagina, B. Abel, and T.J. Scriba Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns Am J Respir Crit Care Med 182 8 2010 1073 1079
22. H. Mulenga, S. Moyo, and L. Workman Phenotypic variability in childhood TB: implications for diagnostic endpoints in tuberculosis vaccine trials Vaccine 29 26 2011 4316 4321
23. M. Hatherill, S. Verver, and H. Mahomed The Taskforce on clinical research issues, Stop TB working group on TB vaccines. Consensus statement on diagnostic endpoints for infant TB vaccine trials Clin Infect Dis 54 2011 493 501
24. P.B. Gilbert, D. Grove, and E. Gabriel A sequential phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens Stat Commun Infect Dis 3 1 2011 Pages -, ISSN (online) 1948-4690, DOI:10.2202/1948-4690.1037, October 2011
25. D. Maiga, B.D. Akanmori, and L. Chocarro Joint reviews and inspections:Strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa Vaccine 28 2009 571 575
26. M.J. Brennan, U. Fruth, and J. Milstien Development of new tuberculosis vaccines: a global perspective on regulatory issues PLoS Med 4 8 August 2007 1299 1302 (Pubitemid 47358163)
27. http://www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM282995.pdf
28. C. Harper Tuberculosis, a neglected opportunity? Nat Med 13 2007 309